Epidemiological and clinical characteristics of patients in pre-intervention and intervention groups
| Characteristic . | All cases (n = 648) . | Pre-intervention group (n = 385) . | Intervention group (n = 263) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| median age, years (IQR) | 67 (55–76.9) | 67.3 (54.3–76.8) | 67 (56–77) | 0.655 |
| male sex | 375 (58%) | 218 (56.6%) | 157 (59.9%) | 0.418 |
| Comorbidities | ||||
| diabetes mellitus | 173 (26.9%) | 94 (24.4%) | 79 (30.5%) | 0.103 |
| chronic kidney failure | 134 (20.9%) | 92 (23.9%) | 42 (16.3%) | 0.023 |
| chronic liver disease | 92 (14.3%) | 67 (17.4%) | 25 (9.7%) | 0.008 |
| chronic lung disease | 118 (18.3%) | 83 (21.6%) | 35 (13.5%) | 0.010 |
| haematological malignancy | 40 (6.2%) | 27 (7%) | 13 (4.9%) | 0.321 |
| solid organ malignancy | 243 (37.6%) | 143 (37.2%) | 100 (38.2%) | 0.869 |
| HSCT | 36 (7%) | 27 (10.5%) | 9 (3.5%) | 0.002 |
| solid organ transplantation | 55 (8.5%) | 32 (8.3%) | 23 (8.9%) | 0.89 |
| HIV infection | 12 (1.9%) | 10 (2.6%) | 2 (0.8%) | 0.137 |
| Charlson index ≥2 | 465 (71.9%) | 284 (74%) | 181 (68.8%) | 0.156 |
| Risk factors for candidaemia | ||||
| central venous catheter | 477 (73.6%) | 299 (77.7%) | 178 (67.7%) | 0.005 |
| neutropenia | 29 (4.5%) | 21 (5.5%) | 8 (3.2%) | 0.243 |
| prior surgery (last month) | 367 (57%) | 222 (57.7%) | 145 (56%) | 0.686 |
| total parenteral nutrition | 290 (48.4%) | 162 (47.8%) | 128 (49.2%) | 0.742 |
| prior corticoid therapy | 166 (25.7%) | 114 (29.6%) | 52 (19.9%) | 0.006 |
| Source of candidaemia | ||||
| primary | 275 (43.4%) | 208 (54%) | 67 (27%) | <0.001 |
| catheter related | 253 (39.8%) | 137 (35.6%) | 116 (46.2%) | 0.008 |
| urinary | 47 (7.5%) | 27 (7%) | 20 (8.2%) | 0.646 |
| abdominal | 43 (7%) | 10 (2.7%) | 33 (13.5%) | <0.001 |
| Severity of infection | ||||
| Pitt score >2 | 178 (29.6%) | 106 (31.4%) | 72 (27.4%) | 0.322 |
| shock at onset | 200 (30.9%) | 104 (27%) | 96 (36.5%) | 0.012 |
| persistent candidaemia | 125 (20.4%) | 73 (19.6%) | 52 (20.6%) | 0.760 |
| Characteristic . | All cases (n = 648) . | Pre-intervention group (n = 385) . | Intervention group (n = 263) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| median age, years (IQR) | 67 (55–76.9) | 67.3 (54.3–76.8) | 67 (56–77) | 0.655 |
| male sex | 375 (58%) | 218 (56.6%) | 157 (59.9%) | 0.418 |
| Comorbidities | ||||
| diabetes mellitus | 173 (26.9%) | 94 (24.4%) | 79 (30.5%) | 0.103 |
| chronic kidney failure | 134 (20.9%) | 92 (23.9%) | 42 (16.3%) | 0.023 |
| chronic liver disease | 92 (14.3%) | 67 (17.4%) | 25 (9.7%) | 0.008 |
| chronic lung disease | 118 (18.3%) | 83 (21.6%) | 35 (13.5%) | 0.010 |
| haematological malignancy | 40 (6.2%) | 27 (7%) | 13 (4.9%) | 0.321 |
| solid organ malignancy | 243 (37.6%) | 143 (37.2%) | 100 (38.2%) | 0.869 |
| HSCT | 36 (7%) | 27 (10.5%) | 9 (3.5%) | 0.002 |
| solid organ transplantation | 55 (8.5%) | 32 (8.3%) | 23 (8.9%) | 0.89 |
| HIV infection | 12 (1.9%) | 10 (2.6%) | 2 (0.8%) | 0.137 |
| Charlson index ≥2 | 465 (71.9%) | 284 (74%) | 181 (68.8%) | 0.156 |
| Risk factors for candidaemia | ||||
| central venous catheter | 477 (73.6%) | 299 (77.7%) | 178 (67.7%) | 0.005 |
| neutropenia | 29 (4.5%) | 21 (5.5%) | 8 (3.2%) | 0.243 |
| prior surgery (last month) | 367 (57%) | 222 (57.7%) | 145 (56%) | 0.686 |
| total parenteral nutrition | 290 (48.4%) | 162 (47.8%) | 128 (49.2%) | 0.742 |
| prior corticoid therapy | 166 (25.7%) | 114 (29.6%) | 52 (19.9%) | 0.006 |
| Source of candidaemia | ||||
| primary | 275 (43.4%) | 208 (54%) | 67 (27%) | <0.001 |
| catheter related | 253 (39.8%) | 137 (35.6%) | 116 (46.2%) | 0.008 |
| urinary | 47 (7.5%) | 27 (7%) | 20 (8.2%) | 0.646 |
| abdominal | 43 (7%) | 10 (2.7%) | 33 (13.5%) | <0.001 |
| Severity of infection | ||||
| Pitt score >2 | 178 (29.6%) | 106 (31.4%) | 72 (27.4%) | 0.322 |
| shock at onset | 200 (30.9%) | 104 (27%) | 96 (36.5%) | 0.012 |
| persistent candidaemia | 125 (20.4%) | 73 (19.6%) | 52 (20.6%) | 0.760 |
Epidemiological and clinical characteristics of patients in pre-intervention and intervention groups
| Characteristic . | All cases (n = 648) . | Pre-intervention group (n = 385) . | Intervention group (n = 263) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| median age, years (IQR) | 67 (55–76.9) | 67.3 (54.3–76.8) | 67 (56–77) | 0.655 |
| male sex | 375 (58%) | 218 (56.6%) | 157 (59.9%) | 0.418 |
| Comorbidities | ||||
| diabetes mellitus | 173 (26.9%) | 94 (24.4%) | 79 (30.5%) | 0.103 |
| chronic kidney failure | 134 (20.9%) | 92 (23.9%) | 42 (16.3%) | 0.023 |
| chronic liver disease | 92 (14.3%) | 67 (17.4%) | 25 (9.7%) | 0.008 |
| chronic lung disease | 118 (18.3%) | 83 (21.6%) | 35 (13.5%) | 0.010 |
| haematological malignancy | 40 (6.2%) | 27 (7%) | 13 (4.9%) | 0.321 |
| solid organ malignancy | 243 (37.6%) | 143 (37.2%) | 100 (38.2%) | 0.869 |
| HSCT | 36 (7%) | 27 (10.5%) | 9 (3.5%) | 0.002 |
| solid organ transplantation | 55 (8.5%) | 32 (8.3%) | 23 (8.9%) | 0.89 |
| HIV infection | 12 (1.9%) | 10 (2.6%) | 2 (0.8%) | 0.137 |
| Charlson index ≥2 | 465 (71.9%) | 284 (74%) | 181 (68.8%) | 0.156 |
| Risk factors for candidaemia | ||||
| central venous catheter | 477 (73.6%) | 299 (77.7%) | 178 (67.7%) | 0.005 |
| neutropenia | 29 (4.5%) | 21 (5.5%) | 8 (3.2%) | 0.243 |
| prior surgery (last month) | 367 (57%) | 222 (57.7%) | 145 (56%) | 0.686 |
| total parenteral nutrition | 290 (48.4%) | 162 (47.8%) | 128 (49.2%) | 0.742 |
| prior corticoid therapy | 166 (25.7%) | 114 (29.6%) | 52 (19.9%) | 0.006 |
| Source of candidaemia | ||||
| primary | 275 (43.4%) | 208 (54%) | 67 (27%) | <0.001 |
| catheter related | 253 (39.8%) | 137 (35.6%) | 116 (46.2%) | 0.008 |
| urinary | 47 (7.5%) | 27 (7%) | 20 (8.2%) | 0.646 |
| abdominal | 43 (7%) | 10 (2.7%) | 33 (13.5%) | <0.001 |
| Severity of infection | ||||
| Pitt score >2 | 178 (29.6%) | 106 (31.4%) | 72 (27.4%) | 0.322 |
| shock at onset | 200 (30.9%) | 104 (27%) | 96 (36.5%) | 0.012 |
| persistent candidaemia | 125 (20.4%) | 73 (19.6%) | 52 (20.6%) | 0.760 |
| Characteristic . | All cases (n = 648) . | Pre-intervention group (n = 385) . | Intervention group (n = 263) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| median age, years (IQR) | 67 (55–76.9) | 67.3 (54.3–76.8) | 67 (56–77) | 0.655 |
| male sex | 375 (58%) | 218 (56.6%) | 157 (59.9%) | 0.418 |
| Comorbidities | ||||
| diabetes mellitus | 173 (26.9%) | 94 (24.4%) | 79 (30.5%) | 0.103 |
| chronic kidney failure | 134 (20.9%) | 92 (23.9%) | 42 (16.3%) | 0.023 |
| chronic liver disease | 92 (14.3%) | 67 (17.4%) | 25 (9.7%) | 0.008 |
| chronic lung disease | 118 (18.3%) | 83 (21.6%) | 35 (13.5%) | 0.010 |
| haematological malignancy | 40 (6.2%) | 27 (7%) | 13 (4.9%) | 0.321 |
| solid organ malignancy | 243 (37.6%) | 143 (37.2%) | 100 (38.2%) | 0.869 |
| HSCT | 36 (7%) | 27 (10.5%) | 9 (3.5%) | 0.002 |
| solid organ transplantation | 55 (8.5%) | 32 (8.3%) | 23 (8.9%) | 0.89 |
| HIV infection | 12 (1.9%) | 10 (2.6%) | 2 (0.8%) | 0.137 |
| Charlson index ≥2 | 465 (71.9%) | 284 (74%) | 181 (68.8%) | 0.156 |
| Risk factors for candidaemia | ||||
| central venous catheter | 477 (73.6%) | 299 (77.7%) | 178 (67.7%) | 0.005 |
| neutropenia | 29 (4.5%) | 21 (5.5%) | 8 (3.2%) | 0.243 |
| prior surgery (last month) | 367 (57%) | 222 (57.7%) | 145 (56%) | 0.686 |
| total parenteral nutrition | 290 (48.4%) | 162 (47.8%) | 128 (49.2%) | 0.742 |
| prior corticoid therapy | 166 (25.7%) | 114 (29.6%) | 52 (19.9%) | 0.006 |
| Source of candidaemia | ||||
| primary | 275 (43.4%) | 208 (54%) | 67 (27%) | <0.001 |
| catheter related | 253 (39.8%) | 137 (35.6%) | 116 (46.2%) | 0.008 |
| urinary | 47 (7.5%) | 27 (7%) | 20 (8.2%) | 0.646 |
| abdominal | 43 (7%) | 10 (2.7%) | 33 (13.5%) | <0.001 |
| Severity of infection | ||||
| Pitt score >2 | 178 (29.6%) | 106 (31.4%) | 72 (27.4%) | 0.322 |
| shock at onset | 200 (30.9%) | 104 (27%) | 96 (36.5%) | 0.012 |
| persistent candidaemia | 125 (20.4%) | 73 (19.6%) | 52 (20.6%) | 0.760 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
